EX-99.2 3 dp220877_ex9902.htm EXHIBIT 99.2

 

Exhibit 99.2

 

   
 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Financial Statements

 

September 30, 2024

 

 

 

Auna S.A. and Subsidiaries

 

Condensed Consolidated Interim
Financial Statements

 

 

September 30, 2024

 

 

Contents Page
   
Condensed Consolidated Interim Statement of Financial Position 1
   
Condensed Consolidated Interim Statement of Income and Other
Comprehensive Income (Loss)		 2
   
Condensed Consolidated Interim Statement of Changes in Equity 3
   
Condensed Consolidated Interim Statement of Cash Flows 4
   
Operating Segments 5 - 10

 

 

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Financial Position
As of September 30, 2024 and December 31, 2023

 

 

In thousands of soles September 30,
2024		 December 31,
2023		   In thousands of soles

September 30,

2024 

 December 31,
2023
Assets       Liabilities    
Current assets       Current liabilities    
Cash and cash equivalents 200,493 241,133   Loans and borrowings 581,802 385,300
Trade accounts receivable 983,896 860,916   Lease liabilities 30,568 31,867
Other assets 214,022 222,728   Trade accounts payable 865,821 749,349
Inventories 133,273 130,521   Other accounts payable 312,989 463,600
Derivative financial instruments 2,725     721   Provisions 18,516 19,074
Other investments 98,024 93,132   Insurance contract liabilities 30,443 39,853
Total current assets 1,632,433 1,549,151   Deferred income 166 267
        Derivative financial instruments 16,088 -
        Total current liabilities 1,856,393 1,689,310
Non-current assets            
Trade accounts receivable 482 420   Non-current liabilities    
Other assets 26,610 21,573   Loans and borrowings 3,020,555 3,376,282
Investments in associates and joint venture 23,785 20,584   Lease liabilities 108,347 126,178
Other investments 266 289   Trade accounts payable 3,141 3,906
Property, furniture, and equipment 2,330,247 2,573,140   Other accounts payable 74,679 221,132
Intangible assets 2,742,878 3,129,187   Deferred tax liabilities 365,078 495,826
Right-of-use assets 123,183 139,386   Deferred income 212 352
Investment properties 6,108 6,959   Derivative financial instruments 52,106 -
Derivative financial instruments 58,726 81,492   Total non-current liabilities 3,624,118 4,223,676
Deferred tax assets 205,022 167,371   Total liabilities 5,480,511 5,912,986
Total non-current assets 5,517,307 6,140,401        
        Equity    
        Share capital 17,387 8,820
        Share premium 1,211,147 -
        Reserves 572,886 1,823,364
        Retained losses (282,262) (366,899)
        Equity attributable to the owner of the Company 1,519,158 1,465,285
        Non-controlling interest 150,071 311,281
        Total equity 1,669,229 1,776,566
Total assets 7,149,740 7,689,552   Total liabilities and equity 7,149,740 7,689,552

1

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Income and Other Comprehensive Income (Loss)
For the three and nine months ended September 30, 2024 and 2023

 

  Three-month period
ended September 30		 Nine-month period
ended September 30
In thousands of soles 2024 2023 2024 2023
Revenue        
Insurance revenue 275,189  278,851  783,721  670,435 
Healthcare services revenue 765,595  667,021  2,300,855  1,987,267 
Sale of medicines 85,907  69,284  238,628  197,286 
Total revenue from contracts with customers 1,126,691  1,015,156  3,323,204  2,854,988 
Cost of sales and services (677,318) (643,172) (2,032,076) (1,795,390)
Gross profit 449,373  371,984  1,291,128  1,059,598 
Selling expenses (54,534) (55,059) (155,437) (151,830)
Administrative expenses (195,185) (176,579) (587,671) (512,040)
Loss for impairment of trade receivables (25,155) (608) (27,990) (3,383)
Other income 54,400  9,552  73,464 37,551 
Operating profit 228,899 149,290  593,494  429,896 
Finance income 34,304  3,300  49,623  54,125 
Finance costs  (137,789) (175,072) (503,164) (443,311)
Net finance cost (103,485) (171,772) (453,541) (389,186)
Share of profit of equity-accounted investees 1,998  1,997  6,514  4,828 
Profit before tax 127,412  (20,485) 146,467  45,538 
 Income tax expense (26,899) 2,979  (46,366) (40,413)
Profit (loss) for the period 100,513  (17,506) 100,101  5,125 
Other comprehensive loss        
Items that are or may be reclassified subsequently to profit or loss        
Cash flow hedges (859) (67,466) (16,780) (25,814)
Foreign operations – foreign currency translation differences (208,764) 139,283  (324,938) 344,924 
Changes in fair value of Put and Call liability -  (3,002) -  42,722 
Other investments at FVOCI – net change in fair value 927  423  1,486  423 
Income tax (expense) benefit 1,108  20,075  4,416  7,683 
Other comprehensive (loss) income for the period, net of tax (207,588) 89,313  (335,816) 369,938 
Total comprehensive (loss) income for the period (107,075) 71,807  (235,715) 375,063 
Income (loss) attributable to:        
Owner of the Company 97,894  (40,528) 88,312  (42,605)
Non-controlling interest 2,619  23,022  11,789  47,730 
  100,513 (17,506) 100,101  5,125 
Total comprehensive income  (loss) attributable to:        
Owner of the Company (102,534) 17,876  (234,415) 236,662 
Non-controlling interest (4,541) 53,931  (1,300) 138,401 
  (107,075) 71,807  (235,715) 375,063 
Earnings per share        
Basic earnings per share 1.32  (0.92)  1.36  (0.97) 
Diluted earnings per share 1.32  (0.92)  1.35  (0.97) 

 

2

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Changes in Equity
For the nine months ended September 30, 2024 and 2023

 

        Equity attributable to the owner of the Company      
 

Share

capital

Share

premium

Other

capital

reserve

 Translation reserve

Cost of

hedging

reserve

Hedging

reserve 

 Fair value reserve

Merger

and other reserves

 Shared-based payment reserve Retained (losses) earnings Total

Non-

controlling

interest

Total

equity

Balances as of January 1, 2023 236,547  386,045  56,314  (190,389) (15,133) (16,756) -  699,333  -  (90,982) 1,064,979  493,082  1,558,061 
Profit for the period -  -  -  -  -  -  -  -  -  (42,605) (42,605) 47,730  5,125 
Other comprehensive income for the period -  -  -  266,425  (13,205) (8,041) 423  33,665  -  -  279,267  90,671  369,938 
Total comprehensive income for the period -  -  -  266,425  (13,205) (8,041) 423  33,665  -  (42,605) 236,662  138,401  375,063 
Dividend distribution -  -  -  -  -  -  -  -  -  -  -  (6,841) (6,841)
Transfer to legal reserve -  -  16,807 -  -  -  -  -  -  (16,807) -  -  - 
Shareholder´s downstream merger (227,727) (386,045) -  -  -  -  -  613,963  -  (2,203) (2,012) -  (2,012)
Changes of participation NCI in subsidiary -  -  -  28,360   (7,284) 10,399  -  283,892  -  -  315,367  (315,367) - 
Contributions from non-controlling Shareholders -  -  -  -  -  -  -  (1,016) -  -  (1,016) 1,032 16 
Total transactions with the owner of the Company (227,727) (386,045) 16,807  28,360  (7,284) 10,399  -  896,839  -  (19,010) 312,339  (321,176) (8,837)
Balances as of September 30, 2023 8,820  -  73,121  104,396  (35,622)  (14,398) 423  1,629,837  -  (152,597)  1,613,980  310,307  1,924,287 
Balances as of December 31, 2023 8,820  -  79,782  140,066  6,422  (29,548) 231  1,626,411  -  (366,899) 1,465,285  311,281  1,776,566 
Loss for the period -  -  -  -  -  -  -  -  -  88,312  88,312  11,789  100,101 
Other comprehensive loss for the period -  -  -  (311,849) (11,789) (575) 1,486  -  -  -  (322,727) (13,089) (335,816)
Total comprehensive loss for the period -  -  -  (311,849) (11,789) (575) 1,486  -  -  88,312  (234,415) (1,300) (235,715)
Issuance of common stock, net of issuance costs 1,112  1,207,474  -  -  -  -  -  -  -  -  1,208,586  -  1,208,586 
Capitalization of merger reserve 7,453  -  -  -  -  -  -  (7,453) -  -  -  -  - 
Reclassification of shared-based payment reserve -  -  -  -  -  -  -  -  3,675  (3,675) -  -  - 
Issuance of shares 2  3,673  -  -  -  -  -  -  (3,675) -  -  -  - 
Acquisition of non-controlling interest -  -  -  18,909  -  -  -  (1,076,628) -  -  (1,057,719) (159,910) (1,217,629)
Derecognition of put and call liability -  -  -  -  -  -  -  131,152  -  -  131,152  -  131,152 
Equity-settled share-based payment -  -  -  -  -  -  -  -  6,269  -  6,269  -  6,269 
Total transactions with the owner of the Company 8,567  1,211,147  -  18,909  -  -  -  (952,929) 6,269  (3,675) 288,288  (159,910) 128,378 
Balances as of September 30, 2024 17,387  1,211,147  79,782  (152,874) (5,367) (30,123) 1,717  673,482  6,269  (282,262) 1,519,158  150,071  1,669,229 

 

3

 

Auna S.A. and Subsidiaries
Condensed Consolidated Interim Statement of Cash Flows
For the nine months ended September 30, 2024 and 2023

 

  Nine-month period ended September 30
In thousands of soles 2024 2023
Cash flows from operating activities    
Profit for the period 100,101  5,125 
Adjustments for:    
Depreciation 89,022  102,854 
Depreciation of right-of-use assets 20,664  19,409 
Amortization 57,567  57,352 
(Reversal) Impairment of inventories                      (3,392) (1,461)
Equity-settled share-based payment transactions 6,269  - 
Loss on disposal of property, furniture, and equipment 1,962  2,110 
Loss (gain) on disposal of right-of-use assets net of leases liabilities 71  (6)
Loss on disposal of intangibles 1,151  307 
Loss for impairment of trade receivables 27,990  3,383 
Share of profit of equity-accounted investees                       (6,514) (4,828)
Technical provisions and other provisions 4,053  871 
Other income for reversal of contingent consideration                                 -    (4,095)
Other income for reversal of others accounts payable to former shareholders (46,613) - 
Finance income                   (49,623) (54,125)
Finance costs 503,164  443,311 
Income tax expense 46,366  40,413 
Net changes in assets and liabilities:    
Trade accounts receivable and other assets                (285,348)  (210,173)
Inventories                      (7,946)  (7,141)
Trade accounts payable and other accounts payable                   163,828 85,651 
Provisions                      (2,260)  (2,052)
Insurance contract liabilities                      (8,403) 36,640 
Cash from operating activities 612,109  513,545 
Income tax paid                 (153,520)  (87,678)
Interest received 16,363  10,649 
Net cash from operating activities 474,952  436,516
Cash flows from investing activities    
Acquisition of subsidiary, net of cash acquired                                 -    (59,994)
Payment for accounts payables to former shareholder                    (18,476) (1,368)
Purchase of properties, furniture, and equipment                    (58,013) (79,875)
Proceeds from sale of property, furniture, and equipment                             216  522 
Purchase of intangibles                    (34,881) (30,692)
Dividends from equity-accounted investees                          1,718 - 
Other assets (Trust funds)                                 -    94,539 
Purchase of other investments                    (16,287) (15,786)
Proceeds from advance payment for purchase of shares                                 -    11,592 
Payment for contingent consideration                    (46,991) (35,088)
Net cash used in investing activities         (172,714) (116,150)
Cash flows from financing activities    
Proceeds from issuance of common stock in initial public offering, net of issuance costs 1,267,794  - 
Payments of initial public offering costs                    (15,908) - 
Proceeds from loans and borrowings                   744,818 2,634,274 
Payment of loans and borrowings                 (701,878) (2,485,779)
Payment of lease liabilities                   (34,028) (31,184)
Payment for derivatives premiums                   (36,458) (15,044)
Payment for costs of Extinguishment of debt                    (16,607) - 
Interest paid                 (317,243) (278,014)
Proceeds from settlement of derivatives - interest rate swaps                            343 - 
Dividend paid                        (1,174) (6,841)
Acquisition of non-controlling interest             (1,217,629) - 
Contributions from non-controlling shareholders                                 -    16 
Net cash used in financing activities       (327,970) (182,572)
Net (decrease) increase in cash and cash equivalents                   (25,732) 137,794 
Cash and cash equivalents at January 1                    241,133 208,694 
Exchange difference on cash and cash equivalents for the period                    (14,908) (9,256)
Cash and cash equivalents at September 30 200,493  337,232 
Transactions not representing cash flows    
Assets acquired through finance lease and other financing 9,119  8,940 
Assets acquired from suppliers in installments 6,455  2,354 

 

4

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

 

Operating Segments

 

A.Basis for segmentation

 

The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.

 

The following summary describes the operations of each reportable segment.

 

Reportable segments Operations
Oncosalud Peru Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer.
Healthcare services in Peru Corresponds to medical services within the network of clinics and health centers in Peru.
Healthcare services in Colombia Corresponds to medical services within the network of clinics and health centers in Colombia.
Healthcare services in Mexico Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico.

 

B.Information about reportable segments

 

Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.

 

5

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

For the three months period ended September 30, 2024:

 

In thousands of soles Reportable segments    

Oncosalud

Peru

 Healthcare services in Peru Healthcare services in Colombia Healthcare services in Mexico Total reportable segments Holding and eliminations Total
2024              
External revenues 262,513  185,194  363,231  315,753  1,126,691                      -    1,126,691 
Inter-segment revenue (i) 10,230  69,800                      -                        -    80,030             (80,030)                     -   
Segment revenue 272,743  254,994  363,231  315,753  1,206,721             (80,030) 1,126,691 
External cost of service            (76,691)          (169,954)          (263,471)          (167,202)          (677,318)                     -             (677,318)
Inter-segment cost of service (i)            (69,847)              (9,227)                     -                        -               (79,074)              79,074                     -   
Segment cost of service          (146,538)          (179,181)          (263,471)          (167,202)          (756,392)              79,074          (677,318)
Gross profit 126,205  75,813  99,760  148,551  450,329                 (956) 449,373 
External selling expenses            (44,449)              (4,995)              (1,083)              (3,861)            (54,388)                 (146)            (54,534)
Segment selling expenses            (44,449)              (4,995)              (1,083)              (3,861)            (54,388)                 (146)            (54,534)
External administrative expenses            (19,932)            (26,586)            (48,237)            (56,530)          (151,285)                     -             (151,285)
Inter-segment administrative expenses                   (94)              (1,176)                     -                        -                 (1,270)                1,270                     -   
Corporate expenses            (15,355)            (12,658)              (2,952)              (2,233)            (33,198)            (10,702)            (43,900)
Segment administrative expenses            (35,381)            (40,420)            (51,189)            (58,763)          (185,753)              (9,432)          (195,185)
Impairment losses on trade receivables                 (246)              (5,898)            (16,258)              (2,715)            (25,117)                   (38)            (25,155)
Other income                   753                 1,796                   884              51,355              54,788                 (388)              54,400
Inter-segment other income 2,464  195                      -                        -    2,659               (2,659)                     -   
Other income                3,217                 1,991                   884              51,355              57,447              (3,047)              54,400
Segment operating profit (loss)              49,346              26,491              32,114            134,567            242,518            (13,619)            228,899
Share of profit of equity accounted investees, net of taxes 646                      -    1,352                      -    1,998                      -    1,998 
Exchange difference, net                 (740)                4,696              (1,952)              (6,013)              (4,009)              32,468              28,459
Interest expense, net              (4,548)            (11,361)            (26,836)            (59,654)          (102,399)            (29,545)          (131,944)
Segment profit (loss) before tax              44,704              19,826                4,678              68,900            138,108            (10,696)            127,412
Other disclosures              
Depreciation and amortization              (8,088)            (10,757)            (10,868)            (22,834)            (52,547)              (2,311)            (54,858)
Capital expenditure              (6,210)            (10,070)            (15,132)            (11,466)            (42,878)              (3,910)            (46,788)
Segment assets  36,025  29,546  (42,947)  (327,618)  (304,994)  (37,756)  (342,750)
Segment liabilities  7,997  17,948  (127,373)  (246,771)  (348,199)  (29,054)  (377,253)

 

6

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

For the three months period ended September 30, 2023:

 

In thousands of soles   Reportable segments    

Oncosalud

Peru

 Healthcare services in Peru Healthcare services in Colombia Healthcare services in Mexico Total reportable segments Holding and eliminations Total
2023              
External revenues 228,356  169,091  323,650  294,059  1,015,156   -    1,015,156 
Inter-segment revenue (i) 8707  60785   -      -    69492   (69,492)  -   
Segment revenue 237,063  229,876  323,650  294,059  1,084,648   (69,492) 1,015,156 
External cost of service  (73,030)  (166,141)  (232,290)   (171,711)   (643,172)  -    (643,172)
Inter-segment cost of service (i)  (59,340)  (9,044)  -   -   (68,384)  68,384  - 
Segment cost of service  (132,370)  (175,185)  (232,290)   (171,711) (711,556)  68,384 (643,172)
Gross profit  104,693  54,691  91,360   122,348   373,092  (1,108)   371,984
External selling expenses  (45,769)  (5,011)  (1,618)  (2,478)  (54,876)  (183)  (55,059)
Segment selling expenses  (45,769)  (5,011)  (1,618)  (2,478)  (54,876)  (183)  (55,059)
External administrative expenses  (18,366)  (24,961)  (42,493)   (56,880)   (142,700)  -   (142,700)
Inter-segment administrative expenses  (338)  (1,146)  -   -   (1,484)  1,484  - 
Corporate expenses  (13,297)  (9,797)  (5,473)  (4,600)  (33,167)  (712)  (33,879)
Segment administrative expenses  (32,001)  (35,904)  (47,966) (61,480) (177,351)  772   (176,579)
Impairment losses on trade receivables  (112)  137  (525)  (107)  (607)  (1)  (608)
Other income 280  2,187  1,433  5,650  9,550  2  9,552 
Inter-segment other income 2593  215   -      -    2,808   (2,808)  -   
Other income 2,873  2,402  1,433  5,650  12,358   (2,806) 9,552 
Segment operating profit (loss) 29,684  16,315  42,684  63,933  152,616   (3,326) 149,290 
Share of profit of equity accounted investees, net of taxes  684  -  1,313  -    1,997  -   1,997
Exchange difference, net  (8,961)  (3,018)  19,643  10,203  17,867  (34,866)  (16,999)
Interest expense, net  (5,608)  (12,012)  (32,613) (76,749) (126,982)  (27,791)  (154,773)
Segment profit (loss) before tax  15,799  1,285  31,027 (2,613)   45,498  (65,983)   (20,485)
Other disclosures              
Depreciation and amortization  (7,768)  (10,240)  (10,617)  (27,948)  (56,573)  (2,209)  (58,782)
Capital expenditure  (9,838)  (10,625)  (17,345)  (7,078)  (44,886)  (3,386)  (48,272)
Segment assets 76,396  30,741  207,992  138,205  453,334   16,412 469,746 
Segment liabilities 69,831  28,259  27,301  139,488  264,879  135,072  399,951 

 

7

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

For the nine months period ended September 30, 2024:

 

In thousands of soles Reportable segments    

Oncosalud

Peru

 Healthcare services in Peru Healthcare services in Colombia Healthcare services in Mexico Total reportable segments Holding and eliminations Total
2024              
External revenues 764,943  541,969  1,089,741  926,551  3,323,204  -  3,323,204 
Inter-segment revenue (i) 29,777  208,944  -  -  238,721           (238,721)   - 
Segment revenue 794,720  750,913  1,089,741  926,551  3,561,925           (238,721) 3,323,204 
External cost of service          (231,214)          (502,367)          (796,509)          (501,986)         (2,032,076) -          (2,032,076)
Inter-segment cost of service (i)          (209,253)            (27,510) -  -             (236,763)            236,763   - 
Segment cost of service          (440,467)          (529,877)          (796,509)          (501,986)         (2,268,839)            236,763          (2,032,076)
Gross profit 354,253  221,036  293,232  424,565  1,293,086               (1,958) 1,291,128 
External selling expenses          (125,696)            (15,195)              (4,397)              (9,543)            (154,831)                 (606)            (155,437)
Segment selling expenses           (125,696)            (15,195)              (4,397)              (9,543)            (154,831)                 (606)            (155,437)
External administrative expenses            (56,903)            (77,819)          (148,839)          (185,980)            (469,541) -             (469,541)
Inter-segment administrative expenses                 (265)              (3,913) -  -                 (4,178)                4,178   - 
Corporate expenses            (47,688)            (42,642)              (8,857)              (6,695)            (105,882)            (12,248)            (118,130)
Segment administrative expenses           (104,856)          (124,374)          (157,696)          (192,675)            (579,601)              (8,070)            (587,671)
Impairment losses on trade receivables                 (144)              (5,494)            (19,256)              (3,130)              (28,024)                     34               (27,990)
Other income                1,944                 4,603                3,662              63,794                74,003                  (539)                73,464
Inter-segment other income 7,969  696  -  -  8,665               (8,665)   - 
Other income                9,913                 5,299                 3,662               63,794                 82,668               (9,204)                73,464 
Segment operating profit (loss)             133,470               81,272             115,545             283,011               613,298             (19,804)              593,494 
Share of profit of equity accounted investees, net of taxes 2,589                      -    3,925                      -    6,514                      -    6,514 
Exchange difference, net              (2,172)                 (459)            (39,659)            (18,219)            (60,509)              42,389            (18,120)
Interest expense, net            (14,996)            (34,532)            (84,622)          (217,964)          (352,114)            (83,307)          (435,421)
Segment profit (loss) before tax            118,891               46,281               (4,811)              46,828             207,189             (60,722)            146,467 
Other disclosures              
Depreciation and amortization (23,852) (31,470) (32,367) (72,901) (160,590) (6,663) (167,253)
Capital expenditure (14,156) (25,914) (36,994) (21,874) (98,938) (9,530) (108,468)
Segment assets  2,236,871  1,000,236          2,329,354  3,180,661  8,747,122   (1,597,382) 7,149,740 
Segment liabilities 1,115,412  647,054  1,360,651  1,992,350  5,115,467  365,044  5,480,511 

 

8

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

For the nine months period ended September 30, 2023:

 

In thousands of soles   Reportable segments    

Oncosalud

Peru

 Healthcare services in Peru Healthcare services in Colombia Healthcare services in Mexico Total reportable segments Holding and eliminations Total
2023              
External revenues 659,964  491,279  857,462  846,283  2,854,988   -    2,854,988 
Inter-segment revenue (i) 27,811  167,375   -     -    195,186   (195,186)  -   
Segment revenue 687,775  658,654  857,462  846,283  3,050,174   (195,186) 2,854,988 
External cost of service  (207,644)  (479,438)  (616,704)  (491,604)  (1,795,390)  -     (1,795,390)
Inter-segment cost of service (i)  (165,202)  (26,485)  -     -     (191,687)  191,687  -   
Segment cost of service  (372,846)  (505,923)  (616,704)  (491,604)   (1,987,077)  191,687  (1,795,390)
Gross profit 314,929  152,731  240,758  354,679  1,063,097  (3,499) 1,059,598 
External selling expenses  (125,350)  (14,475)  (4,546)  (7,006)  (151,377)  (453)  (151,830)
Segment selling expenses  (125,350)  (14,475)  (4,546)  (7,006)  (151,377)  (453)  (151,830)
External administrative expenses  (54,651)  (70,704)  (130,153)   (149,272)   (404,780)  -     (404,780)
Inter-segment administrative expenses  (743)  (3,822)  -     -     (4,565)  4,565  -   
Corporate expenses  (51,576)  (43,017)  (8,419)  (4,600)  (107,612)  352  (107,260)
Segment administrative expenses  (106,970)  (117,543)  (138,572)   (153,872) (516,957)  4,917   (512,040)
Impairment losses on trade receivables  276  1,222  (3,881)  (874)  (3,257)  (126)  (3,383)
Other income 798  4,767  14,309  17,674  37,548  3  37,551 
Inter-segment other income 7,743  712   -     -    8,455   (8,455)  -   
Other income  8,541  5,479  14,309  17,674  46,003  (8,452)  37,551
Segment operating profit (loss)  91,426  27,414  108,068   210,601    437,509   (7,613)   429,896
Share of profit of equity accounted investees, net of taxes 1,731   -    3,097   -    4,828   -    4,828 
Exchange difference, net  (7,485)  (1,295) 96,008  27,759  114,987   (88,724) 26,263 
Interest expense, net  (19,177)  (32,954)  (76,107)   (213,372)  (341,610)  (73,839)   (415,449)
Segment profit (loss) before tax  66,495  (6,835)  131,066   24,988   215,714   (170,176)   45,538
Other disclosures              
Depreciation and amortization  (22,292)  (30,498)  (29,482)  (90,596)  (172,868)  (6,747)  (179,615)
Capital expenditure  (17,274)  (17,766)  (56,819)  (17,275)  (109,134)  (8,019)  (117,153)
Segment assets 2,092,566  911,259  2,308,467  3,854,337  9,166,629    (1,509,918) 7,656,711 
Segment liabilities 1,051,910  622,254  1,391,071  2,412,485  5,477,720  254,704  5,732,424 

 

9

 

Auna S.A. and Subsidiaries
Notes to the Condensed Consolidated Interim Financial Statements
September 30, 2024

 

(i)Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Peru S.A.C. remains.

 

10